SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Attention centers on BioNTechs Nov. 3 earnings and pipeline update, with traders weighing oncology readouts and whether management can convert its pipeline into meaningful progress. Bulls point to ESMO data and potential pipeline guidance, while skeptics cite mixed or failed trial results and leadership-transition concerns.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios Q3 results beat expectations and its full-year outlook rose, but a softer Q4 organic-growth outlook signaling deceleration overshadowed the positives and fueled a sharp selloff. Traders are split between viewing the drop as an overreaction to guidance and seeing it as a justified repricing amid slower messaging growth.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos upcoming Q3 report is the main near-term focus, with traders watching whether oral Wegovy demand and company guidance can improve sentiment amid pressure from Eli Lillys obesity-drug competition. Some expect a stronger report to support a recovery, while others doubt positive results will overcome concerns about management execution and the stocks prolonged weakness.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgens positive Phase 3 IMDELLTRAIMFINZI lung-cancer results, which showed a lower risk of death, are fueling bullish attention alongside fresh highs and strong momentum. Traders are also watching the upcoming earnings report and a Sjgrens disease data update, with some interpreting put activity as hedging rather than outright bearishness.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEP is drawing attention ahead of its earnings call, with traders focused on the distributions sustainability and an unusual overlap in timing with CVR Energys results. The falling share price has fueled fears of a distribution cut and questions about losses, debt and hedging, while some holders argue CVR Energy and asset-sale proceeds could support the partnership.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royces sharp pullback is prompting debate over whether oil and jet-fuel concerns, broader market weakness, and aerospace-sector signals are driving the selling despite no widely cited deterioration in company fundamentals. Traders also point to the UK government-backed narrowbody engine development programme as a long-term positive, though some are frustrated that it has not offset the recent weakness.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco shares are under pressure after lower Q3 results and narrower 2026 production guidance, with traders also pointing to Cigar Lake production concerns and heavy bearish options activity. The selloff has prompted debate between near-term worries about operations and valuation and the longer-term uranium-demand and nuclear-growth thesis.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs quarterly report and weaker-than-expected outlook for holiday-quarter bookings, alongside a daily-user miss, triggered a sharp selloff despite some headline results beating estimates. Traders are split between viewing the drop as a buying opportunity near support and warning that slowing engagement and bookings point to weaker growth.

Karman Holdings, Inc. engages in the design, testing, manufacturing, and sale of dependable missile systems. It offers Payload Protection & Deployment Systems, Aerodynamic Interstage Systems, and Propulsion Systems. The company was founded on August 20, 2020 and is headquartered in Huntington Beach, CA.

Karman Holdings Inc.

Karman Holdings Ord Shs

KRMN is drawing attention amid a volatile bounce in defense and drone stocks, which traders describe as a rotation back into the sector; they also cite the companys missile-defense and space exposure, backlog, and contract prospects. Optimism about a recovery is countered by concerns over the prolonged decline and valuation, while some traders attribute the latest pullback to broad-market weakness.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HHSs temporary policy allowing compounding pharmacies to produce six peptides while regulators review them is driving attention, with traders viewing it as a potential new growth opportunity for Hims & Hers. Reactions are split: some expect the company to benefit from its peptide preparations, while others say the share-price response has been muted and want to see proof of commercial execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Emergents CFO retirement and the appointment of its treasurer as interim successor have fueled concern about leadership and financial risk, with some traders speculating about deeper problems while others view the handoff as routine. Attention is also focused on the upcoming quarterly results for signs of how the companys turnaround is progressing.

Swedish Orphan Biovitrum (BIOVF) Tops Q3 Earnings and Revenue Estimates

Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of +14.52% and +4.09%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026

Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the third quarter of 2026. Participants can access the conference call via webcast and also by visiting the Investors page of Emergents...

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?

Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'

Equity

No plague case has been confirmed, and no government orders have been announced, but outbreak-linked stocks jumped anyway.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS PR Newswire NEW YORK, Sept. 10, 2026 NEW YORK, Sept. 10, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...

Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (Emergent BioSolutions or the Company) (NYSE: EBS) investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EMERGENT BIOSOLUTIONS...

Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (Emergent BioSolutions or the Company) (NYSE: EBS) on behalf of investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON EMERGENT BIOSOLUTIONS...

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$NVAX" data-symbol-id="NVAX" href="https://stocktwits.com/symbol/NVAX" target="_blank">NVAX</a> surged 20%, EBS gained 14%, ARCT rose 13% and MRNA climbed 7% amid the Russian plague scare.</li><li>The rally broadened to protective-equipment, antiviral and immune-profiling stocks, with LAKE gaining 15% and APT and NNVC each rising 13%.</li><li>Russian authorities called the regional situation stable, while the WHO assessed the public risk as low.</li></ul>A Russian lab worker’s unexplained death&nbsp;in a plague research institute sparked a rally across vaccine and biodefense stocks on Monday, with Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS) and Arcturus Therapeutics (ARCT) advancing as retail investors speculated about federal contracts and further gains.NVAX surged 20%,&nbsp;<a href="https://stocktwits.com/symbol/EBS">EBS</a> climbed 14%,&nbsp;<a href="https://stocktwits.com/symbol/ARCT">ARCT</a> gained 13% and&nbsp;<a href="https://stocktwits.com/symbol/MRNA">MRNA</a> rose 7%. Buying spread to protective-equipment suppliers, testing companies and antiviral developers as traders revived familiar outbreak bets.<img src="https://news.stocktwits-cdn.com/outbreak_rally_9d23a20745.png" alt="outbreak rally.png">The rally also extended to protective-equipment makers&nbsp;<a href="https://stocktwits.com/symbol/APT">Alpha Pro Tech (APT)</a>, which rose 13% on Monday, and&nbsp;<a href="https://stocktwits.com/symbol/LAKE">Lakeland Industries (LAKE)</a>, which gained 15%. Antiviral developer&nbsp;<a href="https://stocktwits.com/symbol/NNVC">NanoViricides (NNVC)</a> climbed 13%, immune-profiling company&nbsp;<a href="https://stocktwits.com/symbol/VRAX">Virax Biolabs (VRAX)</a> advanced 10%, and smallpox-drug maker&nbsp;<a href="https://stocktwits.com/symbol/SIGA">Siga Technologies (SIGA)</a> added 3%.&nbsp;Cancer-immunotherapy developer&nbsp;<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio (IBRX)</a>, which also featured in retail discussions about government demand, edged up 1%.&nbsp;&nbsp;<h2 class="st-heading-2">Trump’s Russia Offer Fuels Spending Hopes</h2>“We’ll help,” Trump said on Monday, calling the situation a “big problem for Russia,” Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/us/trump-says-us-will-help-russia-after-siberia-plague-institute-death-2026-10-05/">reported</a>. The remarks came after the death of Darya Shipilova, a 28-year-old lab technician at the Irkutsk Anti-Plague Research Institute in Siberia. She developed pneumonia of unknown origin, prompting quarantine measures and medical observation of people who had contact with her.Russia’s public health agency, Rospotrebnadzor, said samples contained no microorganisms associated with her professional duties and called the regional epidemiological situation stable.&nbsp;The WHO said that the risk to the general population appeared low based on available unofficial information. U.S. Secretary of State Marco Rubio also urged measured attention, calling the situation a “cause for focus,” according&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://edition.cnn.com/2026/10/05/world/video/rubio-says-situation-in-russia-is-cause-for-focus-but-not-alarm">to</a> CNN.The uncertainty nevertheless gave traders a familiar catalyst: the prospect that heightened preparedness could lead to government purchases.<h2 class="st-heading-2">Vaccine Makers Ride Outbreak Bets</h2>Novavax, Moderna and Arcturus have commercial vaccines, but their products do not target plague. Novavax developed Nuvaxovid, a protein-based COVID-19 vaccine containing its Matrix-M adjuvant. Matrix-M enhances immune responses and can be incorporated into other vaccines, giving the company broader vaccine-development and licensing exposure.Moderna markets COVID-19 vaccines, including Spikevax, and the RSV vaccine mRESVIA. Its mRNA tech makes it a familiar name in emerging-pathogen trades.&nbsp;Meanwhile, Arcturus has the commercial COVID-19 vaccine Kostaive and is developing ARCT-2304, an experimental H5N1 pandemic-influenza vaccine. BARDA fully funds the candidate’s Phase 1 study.<h2 class="st-heading-2">Stockpile Suppliers And PPE Makers Rally</h2>Emergent has a direct connection to government purchasing through its medical-countermeasure portfolio. BioThrax and Cyfendus are anthrax vaccines, while ACAM2000 is a smallpox and mpox vaccine. Tembexa, another portfolio product, is a smallpox antiviral. Its $24 million BARDA contract modification for Cyfendus, announced last month, shows its procurement model.&nbsp;Siga supplies TPOXX, a smallpox antiviral, to the Strategic National Stockpile. Lakeland and Alpha Pro Tech provide protective equipment. Lakeland supplies protective clothing, while Alpha Pro Tech manufactures disposable garments, masks and face shields.&nbsp;<h2 class="st-heading-2">Antiviral And Immunotherapy Names Join Rally</h2>Virax Biolabs focuses on immune-response detection and T-cell profiling, including applications in post-acute infection syndromes such as Long COVID. NanoViricides is developing NV-387, an antiviral drug candidate. Because plague is bacterial, its rally reflects broader outbreak sentiment rather than an established plague-treatment opportunity.Meanwhile, ImmunityBio markets Anktiva, a cancer immunotherapy, and develops immune-cell platforms.<h2 class="st-heading-2">How Do Retail Traders Feel About Outbreak Bets?</h2>On Stocktwits, retail sentiment for NVAX and EBS was ‘extremely bullish’ amid ‘extremely high’ message volume. ARCT drew ‘bullish’ sentiment with ‘normal’ chatter, while MRNA sentiment remained ‘neutral’ despite ‘high’ message volume.&nbsp;One user on EBS&nbsp;<a href="https://stocktwits.com/KnuckleSandwich/message/665783238">said</a>: “Contract awards are in bound....good timing with the Russia plague news fueling the momentum!!” The user added: “See you at 15++.. Might even hit 20 by year-end!” Another user on NVAX&nbsp;<a href="https://stocktwits.com/TobySmith1366/message/665803930">sees</a> a return to “operation warp speed” and “throwing billions at NVAX.”One user on APT&nbsp;<a href="https://stocktwits.com/Paretoprincipal/message/665752847">drew parallels</a> with a previous outbreak trade: “Hantavirus took APT from $4.50 to $7.50 this May. The plague should take us even higher.” Another user on NNVC&nbsp;<a href="https://stocktwits.com/insanitywolftrading/message/665786543">noted</a> that “every time there is a pandemic fear this makes a massive run.”So far this year, NVAX has gained 87%, MRNA has surged 589% and ARCT has climbed 139%, while EBS remains down 41%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-musk-trillionaire-sequoia-maguire-investors-starting-to-understand-spacex/cZDsnwARBjv">SPCX Stock Makes Musk A Trillionaire Again: Sequoia's Maguire Says Investors Are Just 'Starting To Understand SpaceX'&nbsp;</a>

Alpha Pro Tech Ltd.

Arcturus Therapeutics Holdings Inc

ImmunityBio Inc

Lakeland Industries, Inc.

Moderna Inc

NanoViricides Inc

Novavax Inc

SIGA Technologies Inc

Virax Biolabs Group Ltd

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.81
Prev Close	$7.22
Open	$7.11
Dividend Yield	0.00%
50-Day Moving Average	$6.47
Beta	2.02
Avg. Volume	1.13M
PE Ratio	-1.92

52-Week High	$14.06
52-Week Low	$4.36
Market Capitalization	$349.17M
EPS (Annual)	$0.9277
Price to Book	1.02
Revenue Per Employee	$825,444.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

EBS Fundamentals